Lung cancer drug brigatinib under Real-World watch in south korea
NCT ID NCT04592523
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study is monitoring the safety and effectiveness of the drug brigatinib in adults with a specific type of advanced lung cancer (ALK-positive NSCLC) in South Korea. Researchers will track side effects and how well the drug controls the cancer in 257 patients who are starting brigatinib for the first time. The goal is to see how the drug performs in everyday medical practice, outside of a controlled clinical trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LYMPHOMA KINASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pusan National University Hospital
Busan, 49241, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- AI-Powered navigation aims to pinpoint tiny lung nodules during surgery